Pentosan polysulfate in patients with bladder pain syndrome/interstitial cystitis: Multicenter randomized controlled double-blind trial

Pivazyan, L.G.; Kasyan, George; Grigoryan, B.; Baibarin, Kirill; Pushkar, D Iu

doi:10.1016/s0302-2838(21)00400-0

Cited by 1 publication

(7 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Regarding the randomized-controlled trials that have shown efficacy, the first was published in 1987 15 and the last in 2021. 14…”

Section: Resultsmentioning

confidence: 99%

“…Statistical analysis showed that treatment in the pentosan group was significantly more effective than in the placebo group ( p = 0.014). 14…”

Section: Resultsmentioning

confidence: 99%

“…In conclusion, 13 clinical trials were included in our systematic review and 7 in the meta-analysis. Nine of them were randomized-controlled trials, [4][5][6][7][13][14][15][16][17] one prospective longitudinal study, 18 and three retrospective studies [19][20][21] (Table 1).…”

Section: Resultsmentioning

confidence: 99%

“…The included studies evaluated the effectiveness and safety of oral PPS versus placebo 5,6,[14][15][16] or other treatment options. For example, intravesical liposome, 18 oral cyclosporine A (CyA), 17 intravesical chondroitin sulfate, 21 and oral hydroxyzine.…”

Section: Resultsmentioning

confidence: 99%

“…4,13 Oral PPS has shown a statistically significant improvement in BPS/IC in five RCTs. Criteria for efficacy evaluation were the average O'Leary-Sant Interstitial Cystitis Symptom Score (ICSI) points change in comparison with initial data 7,14 and the patient's subjective improvement. 6,15,16 However, Holm-Bentzen et al in 1987 published a randomized multicenter placebo-controlled trial on 115 patients with BPS.…”

Section: Resultsmentioning

confidence: 99%

See 4 more Smart Citations

Pentosan polysulfate in patients with bladder pain syndrome/interstitial cystitis with Hunner’s lesions or glomerulations: systematic review and meta-analysis

Grigoryan

Kasyan

Pivazyan

et al. 2022

Therapeutic Advances in Urology

View full text Add to dashboard Cite

Background: Bladder pain syndrome/interstitial cystitis (BPS/IC) is a persistent pain perceived in the urinary bladder region, accompanied by at least one symptom, such as pain worsening with bladder filling and daytime or nighttime urinary frequency without any proven infection or obvious pathology. The aim of this study is to evaluate the efficacy and safety of pentosan polysulfate (PPS) in patients with BPS/IC. Methods: Systematic search was performed by PRISMA checklist. Electronic databases, including PubMed and Cochrane library, were checked until 2021 using keywords: ‘pentosan polysulfate’, ‘pain syndrome’, ‘interstitial cystitis’, and bibliography of relevant papers was checked. Inclusion criteria: Patients with confirmed diagnosis of BPS/IC and cystoscopy criteria – Hunner’s lesions. Exclusion criteria included hypersensitivity, pregnancy, lactation, and oral therapy for BPS/IC in the period of 1 month before the study and abstracts or unpublished papers. Results: In total, 13 clinical trials were included in systematic review and 7 were included in meta-analysis. Studies evaluated the effectiveness and safety of oral PPS versus placebo or other treatment options. In the first meta-analysis, three studies compared oral PPS with placebo: [relative risk (RR) = 2.07, 95% confidence interval (CI): 1.37–3.13, p = 0.0006]. The second meta-analysis of two studies compared oral PPS with another treatment options (intravesical liposome and CyA): (RR = 0.44, 95% CI: 0.10–1.93, p = 0.28). The third meta-analysis of two studies included intravesical regimen of PPS compared with intravesical placebo: (RR = 1.09, 95% CI: 0.54–2.22, p = 0.80). The majority of studies do not report any particular serious side effects. Conclusion: PPS treatment has a statistically significant effect over placebo on the subjective improvement of patients with BPS/IC. There was no difference between PPS and other treatment options. Intravesical regimen of PPS had no significant impact on response rates. None of included studies reported severe side effects after intervention.

show abstract

“…Regarding the randomized-controlled trials that have shown efficacy, the first was published in 1987 15 and the last in 2021. 14…”

Section: Resultsmentioning

confidence: 99%

“…Statistical analysis showed that treatment in the pentosan group was significantly more effective than in the placebo group ( p = 0.014). 14…”

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 3 more Smart Citations

Pentosan polysulfate in patients with bladder pain syndrome/interstitial cystitis with Hunner’s lesions or glomerulations: systematic review and meta-analysis

Grigoryan

Kasyan

Pivazyan

et al. 2022

Therapeutic Advances in Urology

View full text Add to dashboard Cite

show abstract

Pentosan polysulfate in patients with bladder pain syndrome/interstitial cystitis: Multicenter randomized controlled double-blind trial

Cited by 1 publication

References 0 publications

Pentosan polysulfate in patients with bladder pain syndrome/interstitial cystitis with Hunner’s lesions or glomerulations: systematic review and meta-analysis

Pentosan polysulfate in patients with bladder pain syndrome/interstitial cystitis with Hunner’s lesions or glomerulations: systematic review and meta-analysis

Contact Info

Product

Resources

About